Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Journal
The New England journal of medicine
Journal Volume
389
Journal Issue
23
Date Issued
2023-12-07
Author(s)
Fakih, Marwan G
Salvatore, Lisa
Esaki, Taito
Modest, Dominik P
Lopez-Bravo, David P
Taieb, Julien
Karamouzis, Michalis V
Ruiz-Garcia, Erika
Kim, Tae-Won
Kuboki, Yasutoshi
Meriggi, Fausto
Cunningham, David
Chan, Emily
Chao, Joseph
Saportas, Yaneth
Tran, Qui
Cremolini, Chiara
Pietrantonio, Filippo
Abstract
KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS G12C inhibitor sotorasib with panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be an effective strategy.
SDGs
Type
journal article